Targeted sequencing can be used to investigate hotspot cancer-driver mutations in breast cancer and thereafter study mutations that affect signaling pathways conferring anti-HER2 drug resistance [11, 19]. The gene discussed is ERBB2; the disease is breast carcinoma.